TScan Therapeutics Q2 net loss narrows on lower R&D costs

Tscan Therapeutics

12/08/2026 12:12

Overview
US biotech firm's Q2 collaboration revenue fell yr/yr, driven by timing of research activities
Net loss for Q2 narrowed as R&D and G&A expenses declined
Company dosed first patient in pivotal Phase 3 trial, with topline data expected mid-2028

Outlook
Company expects topline readout from Phase 3 ALLOHA-2 trial in mid-2028
TScan plans to initiate Phase 1 studies of TSC-102-A01 and TSC-102-A03 in Q4 2026
Company expects existing cash to fund operations into Q2 2027

Result Drivers
PHASE 3 TRIAL PROGRESS - Co dosed first patient in pivotal Phase 3 ALLOHA-2 trial and expects topline data mid-2028
MANUFACTURING VALIDATION - Positive initial data from Cohort C of Phase 1 ALLOHA study validated commercial-ready manufacturing process, with ~90% first-pass success rate
CLINICAL BENEFIT IN HIGH-RISK PATIENTS - Patients with poor prognostic features in Cohort C showed meaningful clinical benefit from TSC-101

Company press release: ID:nGNX2v8wRD

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration and License Revenue
 
$1.05 mln
 
Q2 Net Loss
 
$30.36 mln
 
Q2 Loss From Operations
 
-$30.49 mln
 
Q2 Loss Per Basic Share
 
$0.23
 
Q2 Operating Expenses
 
$31.54 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 672.4% above its August 11 closing price of $0.78

Reuters Recommended Reads
Aug 10 - Sana Biotechnology Q2 adjusted loss narrows, beats estimates
Aug 10 - Biotech firm Nkarta posts Q2 net loss; cash runway into 2029
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)